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| INTRODUC TI ON
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by progressive loss of dopamine-producing neurons and presents with motor symptoms including bradykinesia, rigidity, tremor, and postural instability. [1] [2] [3] Levodopa (LD), a dopamine precursor, is considered the most effective therapy for treating patients with PD. 4 LD is actively absorbed from the intestines and is rapidly metabolized to dopamine by L-amino acid decarboxylase (L-AAD).
To block the peripheral activity of L-AAD, LD is co-administered with carbidopa (CD), an L-AAD inhibitor that is unable to cross the blood-brain barrier (BBB). The LD/CD combination increases central nervous system (CNS) penetration of exogenously administered LD across the BBB and decreases adverse effects associated with peripheral metabolism of LD to dopamine such as nausea, vomiting, cardiac arrhythmias, and orthostatic hypotension. 5 However, high variability in LD exposure following oral LD/CD 6 can result in suboptimal efficacy due to the rapid absorption and short half-life of LD in the plasma, particularly for patients with advanced PD that have a narrow therapeutic window for LD. 7 The large fluctuations in plasma LD exposure associated with oral administration of LD/CD may not adequately control the motor symptoms and dyskinesia of PD patients and may lead to increased "Off" time (period of significant PD symptoms), decreased "On" time (periods of adequate PD symptomatic control) and increased periods of dyskinesia. val. 9 In a double-blind, double-dummy, double-titration Phase 3 trial conducted in advanced PD patients (the LCIG Horizon study), LCIG has been shown to significantly reduce the "Off" time and increase the "On" time without dyskinesia when compared to the LD/CD oral treatment.
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A new LCIG formulation is currently in development to facilitate 
| ME THODS

| Dissolution study
Dissolution tests for both LD and CD were performed using a USP Apparatus 2 operating at a paddle speed of 25 RPM. The dissolution medium was 500 mL of pH 4.5 acetate buffer and the 5-mL of gel sample (~equivalent to the morning dose) was delivered to the bottom of vessel for testing. An automatic sampler collected 1. and the samples were then analyzed with high-performance liquid chromatography (HPLC). In vitro drug release profiles were determined by plotting the cumulative percent dissolved in vitro at each time point until the full drug release was achieved.
| Bioequivalence study design
This was an open-label, randomized, single dose, 2 period crossover study in healthy subjects. All procedures performed in this study were in accordance with the ethical standards of the Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved by the local institutional review board and written informed consent was obtained from each subject before any study-related procedures were performed. The study had a standard two-period crossover design in which the subjects were randomly assigned in a 1:1 ratio to the two sequences of formulations (Table 1) . A total of 28 subjects were planned to be enrolled in this study (n = 14 per sequence of formulations).
The expectation that there would be some subjects who would not provide data for both periods was taken into account. Power calculations were performed for levodopa C max and AUC inf for the test of the hypothesis of no difference between the formulations. The
calculations were done for a difference defined by a ratio of central values of 0.80 or 1.25 (power is the same for these two ratios). For the cases of complete data for 24 subjects and 28 subjects with an equal number per sequence, the calculated power for levodopa C max was 85.9% and 91.0%, respectively. The power for AUC inf exceeded 99.0%.
For these calculations, the error term variance for the analysis of the natural logarithm of levodopa C max was assumed to be 0.0592. 
| Pharmacokinetics sample collection and bioanalysis
Blood samples for determination of LD and CD plasma concentrations in detail. 12 The analytical method was validated over a concentration range of 10-5000 ng/mL. For levodopa, the intra-assay accuracy was between −4.74% and 7.59% and the intra-assay precision was ≤14.2%, respectively. For levodopa, the inter-assay accuracy was between 0.125% and 2.65% and the inter-assay precision was ≤8.27%, respectively. For carbidopa, the intra-assay accuracy was between −3.93% and 15.2% and the intra-assay precision was ≤12.6%, respectively. For carbidopa, the inter-assay accuracy was between −2.06% and 6.26%
and the inter-assay precision was ≤6.43%, respectively.
| Pharmacokinetic statistical analysis and f 2 test
Non-compartmental methods were used to determine values For statistical analysis, C max and AUC parameters were normalized to the actual dose delivered. The dose delivered was calculated as the difference of the weight of the LCIG cassette before and after dosing minus the weight of LCIG needed for priming.
A linear mixed effects model was used to perform the analysis on logarithmically transformed data. The model included fixed effects for period, formulation, and sequence. The subjects were viewed as a random sample. A 90% confidence interval for the ratio of formulation C max geometric means and the ratio of formulation AUC geometric means was provided by exponentiation of the confidence limits for the difference of the logarithm means within the framework of the linear mixed effects model. The 90% confidence intervals for these ratios were used to perform the 21-sided tests procedure for an assessment on equivalence. A similarity factor f 2 test was used to determine differences between the in vitro dissolution profiles for the LCIG-HV and LCIG-LV commercial formulation.
The methodology for the f 2 test has been previously described.
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| Safety and tolerability
Safety and tolerability were assessed throughout the study. All adverse events (AEs) reported from the time of NJ tube placement until 30 days following discontinuation of study drug administration had elapsed were collected. In addition, serious adverse events (SAEs) and protocol-related non-serious adverse events were collected from the time the subject signed the study-specific informed consent. In addition to spontaneous reports by the subjects and observations by the investigator, adverse events were monitored by 
Scale. Adverse events were coded using Medical Dictionary for Regulatory Activities (MedDRA). The number and percentage of subjects having treatment-emergent adverse events were tabulated by primary System Organ Class (SOC) and preferred term and with a breakdown by formulation.
| RE SULTS
| Dissolution
Results for the dissolution profiles for LCIG-HV and LCIG-LV commercial formulations for LD and CD are shown in Figures 1 and 2 .
The f 2 values for levodopa and carbidopa were 23.9 and 25.0, respectively, comparing the LCIG-HV (test) formulation to the LCIG-LV commercial (reference) formulation.
| Participants in bioequivalence study
Twenty-eight subjects were enrolled in this study. Demographic information for all subjects is presented in Table 2 . Two subjects completed the first period of the study but not the second period. There was difficulty placing the NJ tube for one subject in Cohort 1 during Period 1 (LCIG-LV commercial) and a decision was made by the primary investigator not to attempt placing the NJ tube for this subject during Period 2 (LCIG-HV); therefore, the subject was prematurely discontinued. For an additional subject in Cohort 1 the NJ tube could not be successfully placed for Period 2 (LCIG-HV) and the subject was prematurely discontinued. All available data were used in the PK analysis and BE assessment.
Overall, the NJ tube placement and LCIG administration were well tolerated in 28 healthy volunteers. The most common AEs reported with reasonable possibility of being related to either LCIG formulation were nausea and vomiting. The nausea and vomiting AEs typically resolved within an hour of onset. The occurrence of AEs did not appear to be different between the 2 LCIG formulations. There were no SAEs in the study and no premature discontinuations due to AEs. A summary of all AEs from the current study can be found in Table 3 .
| Bioequivalence study
PK results are available for the 28 subjects who received the LCIG-LV commercial formulation and 26 subjects who received the LCIG-HV formulation. PK profiles confirm that both LCIG formulations were successfully delivered to all subjects through the NJ tube.
Pharmacokinetic results from the study show that the levodopa and carbidopa PK profiles appear to be comparable for the LCIG-LV commercial and LCIG-HV formulations (Figure 3) . Summary statistics for all of the PK parameters, normalized by dose delivered, are presented for both formulations in Table 4 . The median T max was 1.0 hour for levodopa and 3.0 hours for carbidopa and showed no apparent difference between formulations. The harmonic mean t 1/2 was 1.6 and 2.0 hours for levodopa and carbidopa, respectively, with no apparent differences between formulations. The geometric means of C max , AUC t and AUC inf were very similar between the 2 formulations with the coefficient of variation percent ranging from 21 to 55%.
In the results of the statistical analysis for C max and AUC, the point estimate for the levodopa C max geometric mean of the LCIG-HV formulation was 4% higher than the point estimate for the LCIG-LV commercial formulation. The levodopa point estimates for AUC t and AUC inf parameters were nearly identical for the two formulations (Table 5 ). For carbidopa, the point estimates of the C max , AUC t and AUC inf geometric means for the LCIG-HV formulation were 3%-4% higher than the point estimates for the LCIG-LV commercial formulation (Table 6 ). For all PK parameters for levodopa and carbidopa the 90% confidence interval for the ratio of the geometric mean of the LCIG-HV formulation to geometric mean of the LCIG-LV commercial formulation falls within the 0.8-1.25 range.
F I G U R E 1 Levodopa dissolution profiles for LCIG-LV commercial and LCIG-HV formulations
F I G U R E 2 Carbidopa dissolution profiles for LCIG-LV commercial and LCIG-HV formulations
| D ISCUSS I ON
The Levodopa-Carbidopa Intestinal Gel system is intended for the long-term treatment of motor fluctuations in patients with advanced idiopathic PD who are no longer adequately controlled by oral PD medications. The commercially available and next generation LCIG formulations are enteral suspensions in an aqueous gel that contains carmellose sodium (carboxymethylcellulose sodium) as the gelling agent. Levodopa is absorbed quickly and effectively from the small intestine through a high capacity transport system for amino acids. 15, 16 Carbidopa, a decarboxylase inhibitor that is administered with levodopa to increase the bioavailability and decrease the clearance of levodopa, has slower and more variable absorption than levodopa and is believed to have a transport mechanism different from that of levodopa.
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The current study demonstrates that although the LCIG-LV commercial and LCIG-HV formulations are clinically bioequivalent for levodopa and carbidopa according to FDA guidance, these formulations have different dissolution profiles in vitro. The f 2 values for levodopa and carbidopa were 23.9 and 25.0, respectively, comparing the LCIG-HV and LCIG-LV formulations. This suggests that the dissolution profiles are not similar according to the FDA guidance, which specifies an f 2 value ≥50 is required. 18, 19 The dissolution method used in this study was designed to provide sufficient discriminating capability against formulation and process attributes. A paddle speed of 25 RPM provided sufficient capability to discriminate the minor differences of the samples and dissolution at pH 4.5 provided the most relevant profiles since this pH is similar to the duodenum-jejunal environment. In addition, CD is not stable at pH 6.8 and significant degradation was expected during testing at this pH. Since this would result in an inaccurate assessment of the dissolution rate, pH 4.5 is the most appropriate condition for dissolution assessment. However, this method was overly sensitive to the sample viscosity, a non-critical characteristic to in vivo performance. Therefore, the in vitro dissolution results that were observed are not clinically relevant to the in vivo drug absorption. These in vitro and in vivo observations also suggest that USP apparatus 2-based dissolution testing may not be appropriate of patients. 20 Furthermore, a separate study in which oral immediate release levodopa and carbidopa was administered to PD patients reported levodopa values well above the 2000 ng/mL level suggesting that Parkinson's disease patients can tolerate higher levodopa exposure than healthy volunteers. 
| CON CLUS IONS
The results from this study demonstrate that the LCIG-LV and LCIG-HV formulations are clinically bioequivalent for levodopa and carbidopa. However, the dissolution method was overly discriminating on the formulation differences.
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